Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2017Advances in TherapyOpen Access

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAndrew DaviesSemmelweis UniversityCBClaude BergeRoche (Switzerland)ABAxel BoehnkeRoche (Switzerland)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Davies et al. (2017) studied this question.

synapsesocial.com/papers/6a19ddab443d3ecd7cdf1a3fhttps://doi.org/10.1007/s12325-017-0610-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study2017 · 76 citations
  2. 2Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen2013 · 39 citations
  3. 3Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical Trials2009 · 191 citations
  4. 4Assessment and Implication of the Allergic Sensitivity to a Single Dose of Recombinant Human Hyaluronidase Injection2007 · 74 citations
  5. 5Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study2014 · 98 citations